Stay updated with breaking news from Vera Bril. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The trial for former neurologist Jeffrey (Scott) Sloka began two and a half years ago, and it remains unclear when there may be a verdict.
Researchers presented data from an open-label extension study following the phase 3 MycarinG trial of rozanolixizumab and the ADAPT-SC+ study of efgartigimod.
VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0001) showing 68% of VYVGART-treated patients were responders
VYVGARTⓇis the first-and-only neonatal Fc receptor (FcRn) blockerauthorized for salein CanadaApproval based on thepositivePhase 3 ADAPTtrial(p<0.0001)showing68% ofVYVGART-treatedpatients wereresponders on the MG-ADL scale compared to 30% of placebo patients after one
21.09.2023 - VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p